Answered

Get detailed and reliable answers to your questions with IDNLearn.com. Ask anything and receive thorough, reliable answers from our community of experienced professionals.

Which of the following is appropriate clinical management for a patient who develops a grade 2 gastrointestinal reaction (immune-related adverse event) associated with the use of immune checkpoint inhibitor therapy?

A. Permanently discontinue checkpoint inhibitor therapy, give steroids, monitor for worsening symptoms
B. Continue checkpoint inhibitor therapy, monitor the patient for worsening symptoms
C. Hold checkpoint inhibitor therapy, give steroids, and resume therapy if symptoms resolve
D. Hospitalize the patient, hold checkpoint inhibitor therapy, give steroids, and closely monitor the patient

Sagot :

GinnyAnsweridn

Final answer:

The appropriate clinical management for grade 2 immune-related adverse events includes holding the therapy, giving steroids, and resuming if symptoms improve.


Explanation:

The appropriate clinical management for a patient who develops a grade 2 gastrointestinal reaction associated with the use of immune checkpoint inhibitor therapy involves holding the checkpoint inhibitor therapy, giving steroids, and resuming therapy if symptoms resolve.

Steroids play a crucial role in managing immune-related adverse events as they help suppress the immune system's response and reduce inflammation, aiding in symptom relief.

This approach helps balance treating the adverse reaction while aiming to continue the beneficial effects of the checkpoint inhibitor therapy.


Learn more about Immune-related adverse events management here:

https://brainly.com/question/32223036


We appreciate your presence here. Keep sharing knowledge and helping others find the answers they need. This community is the perfect place to learn together. Thank you for visiting IDNLearn.com. We’re here to provide dependable answers, so visit us again soon.